Analysts split on Amylin's Byetta
Sanofi aventis' Acomplia -- if it wins FDA approval -- could also impact Byetta. Sanofi is seeking an obesity indication for the drug, but if it gets approved for type 2 diabetes, it could steal some share from Byetta because it too offers the advantage of weight loss.
Sanofi said last week the FDA pushed back its timeframe for making a decision on Acomplia from April 26 to July 27. The company did not divulge the reasons for the delay. Acomplia, which has been launched in 12 countries so far, generated 31 million euros in sales last year.
Sanofi said last week the FDA pushed back its timeframe for making a decision on Acomplia from April 26 to July 27. The company did not divulge the reasons for the delay. Acomplia, which has been launched in 12 countries so far, generated 31 million euros in sales last year.
